Federal Register / Vol. 86, No. 36 / Thursday, February 25, 2021 / Notices 11533 

participate in the survey. We anticipate 

that approximately 20% of SSPs will 

decline to complete the survey, yielding 

approximately 320 completed surveys 

per year. However, given that this is the 

first survey of SSPs funded by CDC and 

that the COVID–19 pandemic makes it 

challenging to predict future response 

rates, we are requesting enough burden 

hours to allow 100% of SSPs to respond 

to the survey. We estimate that it will 

take 35 minutes to complete the survey, 

regardless of how the respondent 

chooses to complete it (i.e., selfadministered online or intervieweradministered by phone or 

videoconferencing). SSPs that do not 

respond to the initial survey invitation 

will be given reminders to complete the 

survey over the duration of the survey 

implementation period. The final 

reminder will include a link to a single 

question for SSPs that choose not to 

complete the survey about why they 

declined to complete the survey. Given 

the uncertainties in response rates 

described above, we are requesting 

enough burden hours to allow 100% of 

SSPs to respond to this question. We 

estimate that it will take two minutes to 

respond to this question. 

OMB approval is requested for three 

years. The survey will be administered 

annually using the most updated 

national directory of SSPs during each 

survey administration. Participation is 

voluntary and there are no costs to 

respondents other than their time. 

ESTIMATED ANNUALIZED BURDEN HOURS

Type of respondent Form Number of 

respondents 

Number of 

responses per 

respondent 

Average 

burden per 

response 

(in hours) 

Total burden 

(in hours) 

All participating SSPs ....................... National Syringe Services Program 

Evaluation Survey.

400 1 35/60 233 

Non-responding SSPs ...................... Non-Response Survey Item ............. 400 1 2/60 13 

Total ........................................... ........................................................... ........................ ........................ ........................ 246 

Jeffrey M. Zirger, 

Lead, Information Collection Review Office, 

Office of Scientific Integrity, Office of Science, 

Centers for Disease Control and Prevention. 

[FR Doc. 2021–03924 Filed 2–24–21; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

[60Day–21–1266; Docket No. CDC–2021– 

0014] 

Proposed Data Collection Submitted 

for Public Comment and 

Recommendations 

AGENCY: Centers for Disease Control and 

Prevention (CDC), Department of Health 

and Human Services (HHS). 

ACTION: Notice with comment period. 

SUMMARY: The Centers for Disease 

Control and Prevention (CDC), as part of 

its continuing effort to reduce public 

burden and maximize the utility of 

government information, invites the 

general public and other Federal 

agencies the opportunity to comment on 

a proposed and/or continuing 

information collection, as required by 

the Paperwork Reduction Act of 1995. 

This notice invites comment on a 

proposed information collection project 

titled ‘‘HIV prevention among Latina 

transgender women who have sex with 

men: Evaluation of a locally developed 

intervention’’. The collection is part of 

a research study designed to evaluate 

the efficacy of a locally developed and 

culturally congruent two-session 

Spanish-language small-group 

intervention, ChiCAS (Chicas Creando 

Acceso a la Salud [Chicas: Girls Creating 

Access to Health]), which provides 

combination HIV prention services to 

adult Hispanic/Latina transgender 

women at high risk for HIV infection. 

DATES: CDC must receive written 

comments on or before April 26, 2021. 

ADDRESSES: You may submit comments, 

identified by Docket No. CDC–2121– 

0014 by any of the following methods: 

• Federal eRulemaking Portal: 

Regulations.gov. Follow the instructions 

for submitting comments. 

• Mail: Jeffrey M. Zirger, Information 

Collection Review Office, Centers for 

Disease Control and Prevention, 1600 

Clifton Road, NE, MS–D74, Atlanta, 

Georgia 30329. 

Instructions: All submissions received 

must include the agency name and 

Docket Number. CDC will post, without 

change, all relevant comments to 

Regulations.gov. 

Please note: Submit all comments 

through the Federal eRulemaking portal 

(regulations.gov) or by U.S. mail to the 

address listed above. 

FOR FURTHER INFORMATION CONTACT: To 

request more information on the 

proposed project or to obtain a copy of 

the information collection plan and 

instruments, contact Jeffrey M. Zirger, 

Information Collection Review Office, 

Centers for Disease Control and 

Prevention, 1600 Clifton Road NE, MS– 

D74, Atlanta, Georgia 30329; phone: 

404–639–7570; Email: omb@cdc.gov 

SUPPLEMENTARY INFORMATION: Under the 

Paperwork Reduction Act of 1995 (PRA) 

(44 U.S.C. 3501–3520), Federal agencies 

must obtain approval from the Office of 

Management and Budget (OMB) for each 

collection of information they conduct 

or sponsor. In addition, the PRA also 

requires Federal agencies to provide a 

60-day notice in the Federal Register 

concerning each proposed collection of 

information, including each new 

proposed collection, each proposed 

extension of existing collection of 

information, and each reinstatement of 

previously approved information 

collection before submitting the 

collection to the OMB for approval. To 

comply with this requirement, we are 

publishing this notice of a proposed 

data collection as described below. 

The OMB is particularly interested in 

comments that will help: 

1. Evaluate whether the proposed 

collection of information is necessary 

for the proper performance of the 

functions of the agency, including 

whether the information will have 

practical utility; 

2. Evaluate the accuracy of the 

agency’s estimate of the burden of the 

proposed collection of information, 

including the validity of the 

methodology and assumptions used; 

3. Enhance the quality, utility, and 

clarity of the information to be 

collected; and 

4. Minimize the burden of the 

collection of information on those who 

are to respond, including through the 

use of appropriate automated, 

electronic, mechanical, or other 

technological collection techniques or 

11534 Federal Register / Vol. 86, No. 36 / Thursday, February 25, 2021 / Notices 

other forms of information technology, 

e.g., permitting electronic submissions 

of responses. 

5. Assess information collection costs. 

Proposed Project 

HIV prevention among Latina 

transgender women who have sex with 

men: Evaluation of a locally developed 

intervention (OMB Control No. 0920– 

1266, Exp. 6/30/2021)—Revision— 

National Center for HIV/AIDS, Viral 

Hepatitis, STED, and TB Prevention 

(NCHHSTP), Centers for Disease Control 

and Prevention (CDC). 

Background and Brief Description 

The National Center for HIV/AIDS, 

Viral Hepatitis, STD and TB Prevention 

is requesting approval for a two-year 

extension of a currently approved ICR, 

0920–1266 entitled, ‘‘HIV prevention 

among Latina transgender women who 

have sex with men: Evaluation of a 

locally developed intervention.’’ The 

goal of this study is to evaluate the 

efficacy of ChiCAS (Chicas Creando 

Acceso a la Salud [Chicas: Girls Creating 

Access to Health]), a locally developed 

and culturally congruent two-session 

Spanish-language small-group 

combination intervention designed to 

promote consistent condom use, and 

access to and participation in preexposure prophylaxis (PrEP) and 

medically supervised hormone therapy 

by HIV seronegative Hispanic/Latina 

transgender women who have sex with 

men. 

The information collected through 

this study will be used to evaluate 

whether the ChiCAS intervention is an 

effective HIV-prevention strategy by 

assessing whether exposure to the 

intervention results in improvements in 

participants’ health and HIV prevention 

behaviors. The study will compare pre- 

(baseline) and post-intervention (sixmonth) levels of HIV risk among 

participants who have received the 

intervention and participants who have 

not yet received the intervention 

(delayed-intervention group). 

This study will be carried out in 

metropolitan areas in and around North 

Carolina including Ashville, NC; 

Charlotte, NC; Research Triangle 

(metropolitan area of Greensboro, 

Winston-Salem and High Point NC); 

Raleigh, NC; Wilmington, NC; and 

Greenville, SC. The study population 

will include 140 HIV-negative Spanishspeaking transgender women. 

Participants will be adults, at least 18 

years of age, self-identify as male-tofemale transgender or report having 

been born male and identifying as 

female, and report having sex with at 

least one man in the past six months. 

We anticipate participants will be 

comprised mainly of racial/ethnic 

minority participants under 35 years of 

age, consistent with the epidemiology of 

HIV infection among transgender 

women. Intervention participants will 

be recruited to the study through a 

combination of approaches, including 

traditional print advertisement, referral, 

in-person outreach, and through word of 

mouth. 

A quantitative assessment will be 

used to collect information for this 

study, which will be delivered at the 

time of study enrollment and again at 

six-month follow up. The assessment 

will be used to measure differences in 

sexual risk knowledge, perceptions and 

behaviors including condom use, PrEP 

use and use of medically supervised 

hormone therapy. Intervention 

mediators, including healthcare 

provider trust and communication 

skills, self-reported health status and 

healthcare access, community 

attachment and social support will also 

be measured. All participants will 

complete the assessment at baseline and 

again at six-month follow-up after 

enrolling in the study. The intervention 

group will participate in ChiCAS after 

completing the baseline assessment and 

the delayed intervention group will 

participate in ChiCAS after completing 

the six-month follow up assessment. 

We will also examine intervention 

experiences through in-depth interviews 

with 30 intervention group participants. 

The interviews will capture 

participants’ general experiences with 

the ChiCAS intervention, as well as 

their experiences and perceptions 

specific to the main study outcomes: 

PrEP knowledge, awareness, interest 

and use; condom skills and use; and 

hormone therapy knowledge, 

awareness, interest and use. 

It is expected that 50% of transgender 

women screened will meet study 

eligibility. We expect the initial 

screening and contact information 

gathering to take approximately four 

minutes to complete. The baseline 

assessment will take 60 minutes (one 

hour) to complete and will be 

administered to 140 participants. The 

follow up assessment will take 45 

minutes (0.75 hours) to complete and 

will be administered to 140 participants 

one time. The interview will take 90 

minutes (one and one-half hours) to 

complete and will be administered to 30 

participants from the intervention group 

one time. 

There are no costs to the respondents 

other than their time. The total number 

of burden hours is 310 across 39-months 

of data collection. The total estimated 

annualized burden hours are 155. 

ESTIMATED ANNUALIZED BURDEN HOURS

Type of respondents Form name 

Number 

of respondents 

Number of 

responses 

per 

respondent 

Average 

burden per 

response 

(in hours) 

Total burden 

(in hours) 

General Public—Adults ..................................... Eligibility Screener ............................................ 140 1 3/60 7 

General Public—Adults ..................................... Contact Information .......................................... 70 1 1/60 2 

General Public—Adults ..................................... Baseline Assessment ........................................ 70 1 1.0 70 

General Public—Adults ..................................... Follow-up Assessment ...................................... 70 1 45/60 53 

General Public—Adults ..................................... Interview ............................................................ 15 1 1.5 23 

Total ............................................................ ........................................................................... ........................ ........................ ........................ 155 

Jeffrey M. Zirger, 

Lead, Information Collection Review Office, 

Office of Scientific Integrity, Office of Science, 

Centers for Disease Control and Prevention. 

[FR Doc. 2021–03925 Filed 2–24–21; 8:45 am] 

BILLING CODE 4163–18–P